Levosulpiride

Specifications

23672-07-3CAS Number

682-417-3EC Number

N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-methoxy-5-sulfamoylbenzamideIUPAC Name

C15H23N3O4SChemical Formula

341.4 g/molMolecular Weight

Levosulpiride; 23672-07-3; (-)-Sulpiride; Levopraid; Levopride; L-Sulpiride; Levosulpirida; Levobren; lesuride; Levosulpiridum; Sulpiride, (s)-; Sulpiride, (-)-; JTG7R315LK; (-)-N-(((S)-1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide; (S)-(-)-N-((1-Ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide; S-(-)-N-(1-Ethyl-2-pyrrolidinomethyl)-2-methoxy-5-sulfamoylebenzamide; CHEBI:64119; Sulpiride l-; RefChem:153234; N05AL07; N-(((S)-1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide; (S)-(-)-sulpiride; S-(-)-Sulpiride; (S)-sulpiride; Levosulpiride [INN]; DTXSID0042583; N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2-methoxy-5-sulfamoylbenzamide; Sulpiride l-form; MFCD00055220; RV-12309; (S)-(-)-5-aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide; Benzamide, 5-(aminosulfonyl)-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-methoxy-; N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-methoxy-5-sulfamoylbenzamide; Levosulpiride (INN); NCGC00024853-05; Levosulpiridum [INN-Latin]; Levosulpirida [INN-Spanish]; DTXCID8022583; Nexipride; (S)-N-((1-ethylpyrrolidin-2-yl)methyl)-2-methoxy-5-sulfamoylbenzamide; SMR000466366; CAS-23672-07-3; SULPIRIDE,(+); UNII-JTG7R315LK; Levogastrol; Sulpiride-l; Sulpiride-S; (S)-N-[(1-Ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide; BENZAMIDE, 5-(AMINOSULFONYL)-N-(((2S)-1-ETHYL-2-PYRROLIDINYL)METHYL)-2-METHOXY-; N-[((2S)-1-ethylpyrrolidin-2-yl)methyl](6-methoxy-3-sulfamoylphenyl)carboxamid e; Levopraid (TN); CAS-15676-16-1; Tocris-0895; Sulpiride [L-(-)]; Biomol-NT_000030; Levosulpiride (Levogastrol); Lopac0_001089; SCHEMBL70112; GTPL958; MLS000759490; MLS001424014; LEVOSULPIRIDE [MART.]; LEVOSULPIRIDE [WHO-DD]; SULPIRIDE L-FORM [MI]; BPBio1_001221; CHEMBL267044; orb1309390; SCHEMBL29406121; BDBM81774; Levosulpiride - Bio-X trade mark; HMS2051A08; HMS2089E04; HMS2232P10; HMS3263I20; HMS3266P14; HMS3411D20; HMS3675D20; HMS3884H07; HY-B1059; Tox21_110933; Tox21_501089; EBC-13802; HB1836; PDSP1_000516; PDSP1_000620; PDSP1_001649; PDSP2_000514; PDSP2_000616; s2104; SBB058180; AKOS007930553; AKOS015897363; Tox21_110933_1; AC-6821; CCG-100847; CS-4581; FL24886; KS-5103; LP01089; NC00097; SDCCGSBI-0051059.P002; 5-(Aminosulfonyl)-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-methoxy-benzamide; Benzamide, 5-(aminosulfonyl)-N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-, (S)-; Benzamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoyl-, S-(-)-; NCGC00015966-10; NCGC00016718-01; NCGC00024853-01; NCGC00024853-02; NCGC00024853-03; NCGC00024853-04; NCGC00024853-06; NCGC00024853-09; NCGC00024853-11; NCGC00261774-01; BL166176; SY057391; CAS_15676-16-1; (S)-(-)-Sulpiride, >=98% (titration); EU-0101089; I0821; NS00076154; ST50319539; SW197477-2; D07312; H11356; S 7771; AB00639965-06; AB00639965-08; AB00639965_09; EN300-7390775; F812867; SR-01000076136; SR-01000597436; Q1452256; SR-01000076136-2; SR-01000597436-1; BRD-K51671335-001-01-5; BRD-K51671335-001-04-9; BRD-K51671335-001-09-8; BRD-K51671335-001-10-6; (S)-(-)-Sulpiride, VETRANAL(TM), analytical standard; (-)-N-[(1-Ethyl-2-pyrrolidinyl)methyl]-5-sulfamoyl-o-a nisamide; (-)-5-Aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide; N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-methoxy-5-sulfamoyl-benzamide; o-ANISAMIDE, N-((1-ETHYL-2-PYRROLIDINYL)METHYL)-5-SULFAMOYL-, (S)-(-)-; 5-HT6 Serotonin Receptor from rat, recombinant, expressed in HEK 293 cells, membrane suspension; U6XSynonyms